Approved GLP-1 RAs Up To 2025 At present, 11 GLP RAs are approved for treating diabetes, including Exenatide, Liraglutide, Exenatide, Albiglutide, Dulaglutide, Lixisenatide, Beinaglutide, Semaglutide, Oral semaglutide, PEG-loxenatide and Tirzepatide
David Ricks, CEO of Eli Lilly, emphasized the company's aggressive efforts to resolve shortages: "We understand the critical importance of Mounjaro for patients managing their health, and we are accelerating our efforts to increase production
Research involving retatrutide may include: Weight loss and weight reduction mechanisms Metabolic signaling and glucose homeostasis Hormone receptor pharmacology Energy expenditure and lipid metabolism Comparative receptor agonist studies Peptide pharmacodynamics and receptor selectivity Cellular signaling and biomarker analysis Research objectives, peptide concentration, study duration, and analytical methods should always be determined by qualified investigators according to validated laboratory protocols
Despite the potential benefits of these medications, more and more reports are emerging of serious health effects
Diabetes Care (2016) 39:35362
